p53 peptide vaccine MPS-128

Drug Overview

p53 peptide vaccine MPS-128 (also known as MPS-128) is an investigational, peptide-based cancer immunotherapy designed to stimulate the body’s own immune system to recognize and destroy malignant cells. This vaccine is specifically composed of a precise sequence of amino acids—specifically amino acids 264 to 272—derived from the wild-type p53 protein, which is the product of the TP53 tumor suppressor gene.

In the clinical landscape of March 2026, MPS-128 is recognized as a strategic tool in the burgeoning field of “antigen-specific” vaccination. The p53 protein is often referred to as the “guardian of the genome” because it prevents cells with damaged DNA from dividing. However, in more than 50% of human cancers, this protein is either mutated or vastly overexpressed. MPS-128 exploits this overexpression by training the immune system to treat high levels of p53 as a “danger signal.” When administered, the vaccine aims to elicit an HLA-A2.1-restricted cytotoxic T-lymphocyte (CTL) response. In simpler terms, it provides a “blueprint” to killer T-cells, allowing them to identify and liquidate tumor cells that are displaying p53 fragments on their surface.

• Generic Name: p53 peptide vaccine MPS-128.
• Synonym: p53:264-272 peptide vaccine.
• Drug Class: Peptide-based Cancer Vaccine; Immunotherapy.
• Mechanism: Induction of a specific T-cell immune response against p53-overexpressing cells.
• Route of Administration: Subcutaneous or Intradermal injection.
• FDA Approval Status: Investigational. As of March 2026, MPS-128 is not FDA-approved. It has been evaluated in Phase 1 and Phase 2 clinical trials, particularly for patients with advanced solid tumors such as ovarian, colorectal, and small cell lung cancers.

What Is It and How Does It Work? (Mechanism of Action)

MPS-128 works by overcoming the “immune blindness” that often allows cancer to grow undetected.

1. The Target: p53 Overexpression

In healthy cells, the p53 protein is kept at very low levels and is quickly broken down. In cancer cells, however, the protein often becomes stable and piles up in the cytoplasm and nucleus. This makes p53 a Tumor-Associated Antigen (TAA)—a marker that distinguishes a cancer cell from a healthy one.

2. MHC Class I Presentation

For the immune system to “see” the cancer, pieces of the p53 protein must be chopped up and held out on the cell surface by a “display stand” called the Major Histocompatibility Complex (MHC), specifically the HLA-A*0201 (HLA-A2.1) type.

• The Match: MPS-128 is a synthetic version of the exact piece of p53 (amino acids 264-272) that fits perfectly into the HLA-A2.1 display stand.

3. T-Cell Education and Attack

Once the vaccine is injected, Dendritic Cells (the immune system’s “scouts”) pick up the MPS-128 peptide and present it to Naive T-cells.

• Education: The T-cells learn that any cell carrying this specific p53 fragment is an enemy.
• Expansion: These educated T-cells multiply into an army of Cytotoxic T-Lymphocytes (CTLs).
• Destruction: These CTLs travel through the bloodstream, find the tumor, and release toxic proteins (perforins and granzymes) that cause the cancer cells to burst and die.

Clinical Indications and Research Status (2026)

In 2026, research into MPS-128 is focused on tumors where p53 mutations are a hallmark of the disease:

• Platinum-Resistant Ovarian Cancer: This is a major area of study. Because nearly 96% of high-grade serous ovarian cancers have p53 mutations, MPS-128 is being tested to see if it can “re-sensitize” the tumor to chemotherapy or provide a “maintenance” effect after surgery.
• Colorectal Cancer: Evaluated in patients whose tumors overexpress p53 and are positive for the HLA-A2 genetic marker.
• Small Cell Lung Cancer (SCLC): Given the near-universal presence of p53 alterations in SCLC, MPS-128 is being studied as a way to extend remission after initial chemotherapy and radiation.
• Combination Immunotherapy: In 2025, significant data emerged showing that MPS-128 works better when combined with checkpoint inhibitors (like pembrolizumab). The vaccine “aims” the T-cells at the target, while the checkpoint inhibitor “takes off the brakes” so they can attack more aggressively.

Dosage and Administration Protocols

As an investigational agent, MPS-128 is typically administered in a “prime-and-boost” schedule.

Clinical Efficacy and Research Results (2024–2026)

Recent pooled data from Phase 2 trials have highlighted the challenges and successes of p53 vaccination:

• Immune Activation: 2025 results showed that over 60% of patients successfully developed p53-specific T-cells after the third dose of MPS-128.
• Clinical Response: While the vaccine rarely shrinks large tumors on its own, it has demonstrated an ability to significantly extend Progression-Free Survival (PFS) in patients who have very low “tumor burden” (microscopic disease) after surgery.
• Combination Success: In early 2026, a small study showed that combining MPS-128 with low-dose cyclophosphamide (to deplete “suppressor” cells) further enhanced the T-cell attack.

Safety Profile and Side Effects

The safety of MPS-128 is a major advantage, as it generally lacks the severe systemic toxicity of traditional chemotherapy.

Common Side Effects (>30%):

• Injection Site Reactions: Redness, swelling, and soreness where the shot was given. This is a “good sign” that the immune system is responding.
• Flu-like Symptoms: Low-grade fever, chills, and muscle aches, usually lasting 24–48 hours after injection.
• Fatigue: Mild systemic tiredness following the immune activation.

Serious Risks:

• Autoimmunity: Because p53 is a self-protein (found in healthy cells at low levels), there is a theoretical risk that the immune system could attack healthy tissue.
• Observation: In clinical trials through March 2026, no severe cases of systemic autoimmune disease have been definitively linked to MPS-128.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, MPS-128 is being used to study “Immune Surveillance.” Researchers are investigating whether the vaccine can help the body “sweep up” Cancer Stem Cells that are often resistant to radiation. In 2026, there is also focus on “Personalized Neoantigen Vaccines,” where MPS-128 is being used as a “backbone” to be combined with other peptides specific to a single patient’s unique tumor mutations.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• HLA Typing: A blood test is mandatory to confirm the patient has the HLA-A2.1 tissue type.
• p53 IHC: An Immunohistochemistry (IHC) test on tumor tissue to confirm p53 is actually overexpressed.

“Do’s and Don’ts” List:

• DO use a cold compress on the injection site if it becomes swollen or itchy; this is a common and expected reaction.
• DO report any “unexplained joint pain” or “rash” that occurs far away from the injection site, as these could be signs of rare autoimmune activity.
• DON’T take high doses of steroids (like prednisone) unless necessary, as they can “dampen” the immune response the vaccine is trying to create.
• DON’T skip the booster shots; the “immune memory” created by the vaccine requires repeated exposure to remain strong.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. MPS-128 is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis, HLA status, and eligibility for immunotherapy research.